IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis.

Unlabelled: The role of proinflammatory IL-17 cytokine was studied in postmenopausal bone loss between 31 osteopenic and 41 osteoporotic women. The effect of serum IL-17A, soluble receptor activator of NF-κB (sRANK) ligand, and osteoprotegerin (OPG) levels on lumbar bone mineral densities was measured. The results demonstrated an increased IL-17A-mediated sRANK ligand elevation in postmenopausal osteoporotic bone loss.

High prevalence of increased interleukin-17A serum levels in postmenopausal estrogen deficiency.

Objective: Postmenopausal estrogen deficiency is associated with chronic inflammatory events that cause cardiovascular and osteoporosis diseases. The aim of this study was to investigate the relationship between interleukin (IL)-17 and serum estradiol levels, age, and postmenopausal duration, as well as bone loss.

Methods: The relationship between serum IL-17A and estradiol levels was studied in 72 postmenopausal women and 22 premenopausal women.

[HLA class I antibody screening and typing in the sera of dialyzed patients with CDC and ELISA techniques: association with graft survival].

Aim: As generally accepted, HLA antibody screening and typing in dialyzed kidney patients are important for the successful outcome of transplantation.

Method: Authors investigated the serum samples of 133 patients from the north-eastern region of Hungary for HLA class I antibodies with complement dependent cytotoxicity(CDC) and solid phase enzyme linked immunosorbent (ELISA) techniques (Biotest Abscreen and Abident class I), respectively.

Results: The comparison of the results revealed a strong correlation (c2=7,23, p < 0,01) for antibody screening.